- Home
- PZC vs ELTX Comparison
PZC vs ELTX Comparison
Compare PZC & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZC
- ELTX
- Stock Information
- Founded
- PZC 2002
- ELTX 2011
- Country
- PZC United States
- ELTX United States
- Employees
- PZC N/A
- ELTX N/A
- Industry
- PZC Investment Managers
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- PZC Finance
- ELTX Health Care
- Exchange
- PZC Nasdaq
- ELTX Nasdaq
- Market Cap
- PZC 149.1M
- ELTX 121.7M
- IPO Year
- PZC N/A
- ELTX N/A
- Fundamental
- Price
- PZC $6.31
- ELTX $5.13
- Analyst Decision
- PZC
- ELTX Strong Buy
- Analyst Count
- PZC 0
- ELTX 2
- Target Price
- PZC N/A
- ELTX $9.50
- AVG Volume (30 Days)
- PZC 48.2K
- ELTX 49.4K
- Earning Date
- PZC 01-01-0001
- ELTX 05-14-2025
- Dividend Yield
- PZC 4.68%
- ELTX N/A
- EPS Growth
- PZC N/A
- ELTX N/A
- EPS
- PZC N/A
- ELTX N/A
- Revenue
- PZC N/A
- ELTX N/A
- Revenue This Year
- PZC N/A
- ELTX N/A
- Revenue Next Year
- PZC N/A
- ELTX N/A
- P/E Ratio
- PZC N/A
- ELTX N/A
- Revenue Growth
- PZC N/A
- ELTX N/A
- 52 Week Low
- PZC $6.30
- ELTX $3.34
- 52 Week High
- PZC $8.20
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- PZC 43.34
- ELTX 38.47
- Support Level
- PZC $6.02
- ELTX $5.00
- Resistance Level
- PZC $6.24
- ELTX $5.68
- Average True Range (ATR)
- PZC 0.12
- ELTX 0.49
- MACD
- PZC 0.01
- ELTX 0.08
- Stochastic Oscillator
- PZC 51.72
- ELTX 42.74
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.